PCRopsis™ Next Generation Direct PCR™ Technology is Successfully Applied to Urinary Tract Infections

Entopsis PCRopsis™ Reagent RVD with RVD Enhancer + PCRopsis™ Support facilitates PCR amplification of both gram positive and negative bacteria from urine. This approach can make traditional DNA isolation prior to PCR testing for urinary tract infections (UTI) obsolete.

UTIs are a recurrent problem in nursing homes and other settings. Such infections can lead to serious complications if not properly diagnosed early. Symptomatic UTIs result in at least 7 million visits to outpatient clinics, 1 million visits to emergency departments, and 100,000 hospitalizations annually. There’s a need to streamline these routine tests and lower healthcare costs.

The PCRopsis™ research and development team recently completed a validation study showing that PCRopsis™ Reagent RVD with RVD Enhancer, when combined with PCRopsis™ Support, facilitates direct amplification of bacteria in urine through PCR. These Next Generation Direct PCRTM reagents allowed for the detection of less than 50 colony forming units (cfu) per mL of bacteria in urine through PCR, without the need for time-consuming and pricey traditional DNA extraction. People with UTIs typically have 1000s of cfu / mL of bacteria in their urine. As such, PCRopsis™ reagents will be able to process just about any UTI sample.

PCRopsis™ Next Generation Direct PCRTM reagents have previously been shown to facilitate nucleic acid extraction-free amplification of viral, bacterial, and mammalian gene targets in 10 minutes from a variety of samples. This latest report expands these capabilities into a new bio-fluid, urine.